Fudge, director of the National Institute of allergy and infectious diseases (NIAID), briefed the White House on Tuesday, saying that radcivir’s clinical trial reached the main evaluation indicators and had a significant positive effect on shortening the recovery time of patients with new crown. It is reported that 1063 patients from many countries in the world participated in the trial, and the results showed that the recovery rate of the group using radcivir was 31% faster than that of the control group. Gilead science shares rose 5.7% on the positive news.
At the same time, the S & P 500 index rose 76 points, or more than 2.6%, or more than 13% this month, or the best performance since 1974; the Dow rose 532 points, or 2.2%, or 12.4%, which is expected to be the largest monthly increase since 1987.
China’s novel coronavirus pneumonia grandpa accidentally announced the results of a severe clinical trial in April 23rd in Reed website. It showed that the efficacy of Reed’s treatment for severe new crown pneumonia was not satisfactory, but the news was soon deleted.